Expanded Use PK of Dapivirine Vaginal Ring

Pharmacokinetics Clinical Trial

Official title:

An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01952561
• Other study ID #: IPM 034
• Status: Completed
• Phase: Phase 1
• First received: September 17, 2013
• Last updated: August 25, 2016
• Start date: November 2013
• Est. completion date: May 2014

Study information

• Verified date: September 2013
• Source: International Partnership for Microbicides, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationBelgium: Health Authority
• Study type: Interventional

Clinical Trial Summary

Study will evaluate the vaginal and blood pharmacokinetics of dapivirine from a vaginal ring containing 25 mg worn for 1, 2, 4, 8 or 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Key Inclusion Criteria:

1. Women 18 and = 40 years of age who can give written informed consent

2. Available for all visits and consent to follow all procedures scheduled for the trial

3. Healthy, based on medical history, vital signs, physical examination, urinalysis, laboratory evaluations for genital infections, and laboratory evaluations for haematology and chemistry

4. HIV-negative as determined by an HIV test at the time of enrolment

5. On a stable form of contraception, defined as:

• A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR

• Transdermal contraceptive patch for at least 3 months prior to enrolment, OR

• Long-acting progestins for at least 6 months prior to enrolment, OR

• An IUD inserted at least 3 months prior to enrolment, OR

• Have undergone surgical sterilisation at least 3 months prior to enrolment AND willing to use oral contraceptives if necessary to delay menstruation during the vaginal sampling period

6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator/Physician

7. Asymptomatic for genital infections at the time of enrolment

8. Willing to refrain from the use of topical vaginal medications, vaginal products or objects

9. Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening

10. Willing to refrain from participation in any other research trial for the duration of this trial

11. Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts

12. Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit:

• Penile-vaginal intercourse

• Oral contact with her genitalia

13. Hepatitis B and C negative at the time of enrolment.

Key Exclusion Criteria:

1. Currently pregnant or had their last pregnancy outcome within 3 months prior to screening

2. Currently breast-feeding

3. Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening

4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, within 2 weeks prior to enrolment

5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;

6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence

7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial results

8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation

9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection

10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;

11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment

12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone

13. Any serious acute, chronic or progressive or signs of cardiac disease, renal failure, or severe malnutrition

14. Have undergone a hysterectomy

15. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• dapivirine ring

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
International Partnership for Microbicides, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	dapivirine pharmacokinetics in plasma		1,2,4,8 or 12 weeks	No